



Vaccine testing. Ebola and beyond

| | |
|---------------|---|
| Authors | Lipsitch, Marc; Eyal, Nir; Halloran, M Elizabeth; Hernán, Miguel A; Longini, Ira M; Perencevich, Eli N; Grais, RFebecca F |
| Citation | Vaccine testing. Ebola and beyond. 2015, 348 (6230):46-8 Science |
| DOI | 10.1126/science.aaa3178 |
| Publisher | High Wire Press |
| Journal | Science (New York, N.Y.) |
| Rights | Archived with thanks to Science (New York, N.Y.) |
| Download date | 03/10/2021 18:45:08 |
| Link to Item | http://hdl.handle.net/10144/618861 |

down-regulation of NKG2D (9) and to an NK cell desensitization in response not only to NKG2D ligands but also to other molecules that activate NK cells (global desensitization) (10). Furthermore, human tumor cells excrete soluble NKG2D ligand by means of proteolytic shedding, alternative splicing, or exosomal release, thereby reducing the NKG2D ligand surface density on tumor cells (5, 11). NKG2D ligand excretion has also been proposed to reduce NKG2D surface expression (by causing receptor internalization) and to reduce NK cell function (by perpetually binding to NKG2D, thereby desensitizing NK cells) (1, 12), consistent with an immunosuppressive role of excreted NKG2D ligands.

“Immunotherapy of cancer, based on natural killer cells, is an emerging field...”

Murine ULBP-like transcript 1 (MULT1) is a transmembrane protein expressed by tumor cells, and is a mouse ligand for NKG2D (13). Deng *et al.* show that soluble MULT1 (sMULT1) released from tumor cells binds with high affinity to NKG2D and prevents the immunosuppressive chronic interaction of NKG2D with another ligand, RAE-1, which is expressed by macrophages in the tumor microenvironment. By blocking RAE-1-NKG2D interaction sMULT1 reconstitutes NK cell responsiveness to other activating molecules and promotes tumor destruction. Deng *et al.* monitored the growth of different tumor cell lines engineered to release sMULT1. Intriguingly, *in vivo* growth of these sMULT1-releasing tumor cells (in mice) was not accelerated but was instead delayed and paralleled by a higher reactivity of NK cells. Similar effects were observed in mice inoculated with tumor cells that could be induced to release sMULT1 or in mice injected intratumorally with sMULT1. Moreover, in mice with tumors that secreted sMULT1, expression of NKG2D did not decrease, but rather increased. Because monovalent sMULT1 did not affect the responsiveness of purified NK cells *in vitro*, the authors hypothesized that other cells contribute *in vivo* to this phenomenon. Myeloid cells (such as macrophages) in the tumor microenvironment express RAE-1 (14), and in tumor-bearing RAE-1-deficient or NKG2D-deficient mice, higher NK cell activity was observed by Deng *et al.* Thus, sMULT1 enhances tumor

rejection by counteracting NK desensitization in the tumor microenvironment, and restoring NKG2D expression and NK cell activity (see the figure).

A fascinating and unresolved puzzle is why such an array of ligands evolved to bind to NKG2D. It was previously proposed that the needs for distinct cellular responses to different types of stress stimuli, for differential tissue expression, and for different cellular compartmentalization led to the evolution of several highly diverse NKG2D ligands. It was also proposed that the diversity of NKG2D ligands was shaped through the selective pressure of viruses and tumors, as a safeguarding mechanism to counteract viral or tumoral immune escape strategies (5). Deng *et al.* provide an additional mechanism with important implications for tumor immunity: Various NKG2D ligands bind NKG2D with different affinities. Specifically, sMULT1, a high-affinity NKG2D ligand, may compete with lower-affinity ligands in the tumor microenvironment, such as RAE-1, for NKG2D occupancy. sMULT1 may abate desensitization caused by chronic exposure to RAE-1. By blocking the immunosuppressive NKG2D-RAE-1 interaction, sMULT1 may prevent NK cell silencing and, rather, promote NK cell antitumor activity.

For successful translation of these findings into the clinic, it will be important to identify the nature of the NKG2D ligand and the nature of the cells expressing this ligand in human tumor beds, as well as molecular mechanisms causing global NK desensitization. In addition, situations where NKG2D is vital for tumor destruction need to be defined, as in the case of tumors that express high amounts of NKG2D ligand, which would mark them as direct targets for an NK cell attack. Here, alternatives to a direct interception of the desensitizing interaction between NKG2D and its ligands need to be developed to preserve tumoricidal NK activity. For example, signaling pathways downstream of NKG2D involved in NK desensitization could be defined and developed as targets for cancer therapy. ■

REFERENCES

1. E. Ullrich *et al.*, *Oncol Immunology* **2**, e26097 (2013).
2. W. Deng *et al.*, *Science* **348**, 136 (2015).
3. S. Bauer *et al.*, *Science* **285**, 727 (1999).
4. J. Wu *et al.*, *Science* **285**, 730 (1999).
5. D. H. Raulet *et al.*, *Annu. Rev. Immunol.* **31**, 413 (2013).
6. A. Cerwenka, J. L. Baron, L. L. Lanier, *Proc. Natl. Acad. Sci. U.S.A.* **98**, 11521 (2001).
7. A. Diefenbach *et al.*, *Nature* **413**, 165 (2001).
8. N. Guerra *et al.*, *Immunity* **28**, 571 (2008).
9. K. Wiemann *et al.*, *J. Immunol.* **175**, 720 (2005).
10. J. D. Coudert *et al.*, *Blood* **111**, 3571 (2008).
11. H. R. Salih *et al.*, *Front. Biosci.* **13**, 3448 (2008).
12. V. Groh, J. Wu, C. Yee, T. Spies, *Nature* **419**, 734 (2002).
13. L. N. Carayannopoulos *et al.*, *J. Immunol.* **15**, 169 (2002).
14. N. Nausch *et al.*, *Blood* **112**, 4080 (2008).

¹Institute for Molecular Medicine, Goethe University, Frankfurt am Main, Germany. ²Innate Immunity Group, German Cancer Research Center (DKFZ), Heidelberg, Germany. E-mail: a.cerwenka@dkfz-heidelberg.de

VACCINE TESTING

Ebola and beyond

Recent experiences in confronting the Ebola epidemic suggest principles for vaccine efficacy trials in challenging environments

By Marc Lipsitch,^{1*†} Nir Eyal,² M. Elizabeth Halloran,^{3,*} Miguel A. Hernán,⁵ Ira M. Longini,⁶ Eli N. Perencevich,^{7,8} Rebecca F. Grais^{9*}

Many epidemic-prone infectious diseases present challenges that the current West African Ebola outbreak brings into sharp relief. Specifically, the urgency to evaluate vaccines, initially limited vaccine supplies, and large and unpredictable spatial and temporal fluctuations in incidence have presented huge logistical, ethical, and statistical challenges to trial design.

In the Ebola outbreak, long and intense discussion led to broad agreement on the need to evaluate the efficacy of Ebola vaccines through an individually randomized controlled trial (iRCT) (1), with cluster-randomized designs providing

POLICY supplemental information.

However, by the time an iRCT began in Liberia, the ability to estimate vaccine efficacy was threatened by the otherwise welcome declining incidence of Ebola virus infection (2). Other trials, planned to provide evidence on vaccines' direct and indirect (herd immunity) effects, might not be able to include enough Ebola cases to provide statistically robust efficacy estimates (2, 3).

Similar challenges may arise when evaluating vaccines for diseases such as meningococcal meningitis, cholera, Middle East Respiratory Syndrome and other coronavirus infections, vector-borne viral diseases such as dengue and chikungunya, and novel influenza strains. Resource-poor populations continue to be at particularly high risk for such infections (4). We suggest three principles, all well-established in the clinical trials literature and applied to varying degrees in the Ebola vaccine trials, that will be of general use in designing vaccine trials during emergencies [Trials of therapies for infected persons arguably

involve a different set of logistical and ethical challenges (5)]. Each principle is mainly responding to a challenge identified in the Ebola context: block randomization with matching is a response to heterogeneity of incidence; stepped rollout is a response to urgency; and adaptive design is a response to uncertainty.

PRINCIPLE I: BLOCK RANDOMIZATION WITHIN SMALL CENTERS, WITH ANALYSIS MATCHED BY CENTER.

For Ebola and other diseases, participants in different districts might experience a surge in cases and hence in infection risk at different times after randomization, depending on the local dynamics of the epidemic. Incidence is thus likely to be considerably more similar between intervention and control participants within a center than in the population as a whole.

To deal with very different incidence across sites, we suggest that randomization of participants to investigational vaccine or control should take place separately within each center (block randomization) and that vaccine efficacy estimates should be obtained for each center and combined statistically to obtain an overall efficacy estimate. A center would be a relatively small group of persons projected to have relatively homogeneous exposure to Ebola infection over the following months. In practice, centers could be composed of the frontline workers at a single Ebola treatment unit, burial teams in a single district, or geographic subgroups of the general population. Matching the analysis by center therefore compares individuals whose risks are more similar to one another and may thereby improve statistical efficiency (6).

Using block randomization of participants within small centers would also maintain balance (and limit loss of sample size) even if at the analysis phase, it becomes necessary to exclude centers in which data are expected to be unreliable—for example, due to expected failure of vaccine delivery or the cold chain or other overwhelming logistical challenges. Previously, such an approach was successfully used to evaluate approaches to national health insurance in Mexico and ensure that a trial design was “politically robust” (7, 8). If analysis provided evidence of interference by local politicians with the randomization scheme, matched pairs of districts could be removed.

PRINCIPLE II: STEPPED ROLLOUT. Individual centers may become ready to commence a trial at different times because of factors that include vaccine availability, timing of identification of centers and participants in areas of continuing incidence,

establishment of a reliable cold chain for vaccine delivery, setting up of information systems, and contracting available trained personnel for vaccine administration and follow-up. A standard iRCT (see Fig. 1A) would await readiness of all centers before commencing. Instead, stepped rollout initiates the trial promptly in each center as soon as that center is ready (see Fig. 1B). Stepped rollout has been used for logistical (9) or political (7, 8) purposes. A key advantage of this approach is shortening the lag between starting a trial and accruing sufficient person-time (Fig. 1B). Shortening the lag may be particularly important when incidence in an area surges over several weeks due to intense transmission.

10 to 12 months before the trial began (14).

The design of adaptive trials requires the specification of rules by which decisions to add new centers, to continue follow-up in existing centers, or to end the trial for success or futility will be made at various stages (10). This approach also permits adaptive adjustments to shifting conditions in later centers (e.g., availability of vaccine or the need for additional trial arms), based on lessons learned in earlier centers (15).

BROADER APPLICATIONS AND A RESEARCH AGENDA. Each design principle has been employed in other settings to resolve particular challenges of trial design. We believe this combination might find



Administering an Ebola vaccine in Guinea.

PRINCIPLE III: ADAPTIVE DESIGN. Vaccine trials require participants who are expected to be at high risk of infection weeks to months later (after an immune response has been generated). Thus, identification of trial sites relies on predictions of future incidence, which are exceedingly difficult.

The third principle states that centers can be added adaptively, which counters the unpredictability of incidence by allowing flexibility in sample size. Adaptive designs can increase statistical power by continuing to observe participants already in the trial and/or by adding centers or participants according to prespecified rules (10). For example, in the Ebola outbreak, an early estimate of the sample size for the Liberia trial was about 27,000 persons followed for 3 to 4 months (11–13). However, because of spatiotemporal variations in incidence, the follow-up time was extended to

broad application in many such settings and contributes to a larger effort to define common principles and practices for such settings. For example, an Ebola vaccine trial in Guinea has just begun (16) with “ring vaccination”—vaccinating “rings” of contacts and geographic neighbors of confirmed cases, a strategy previously used for smallpox eradication. To evaluate vaccine effectiveness, rings will be randomized such that all individuals in certain rings will be offered experimental Ebola vaccine immediately upon identification of a case of infection, whereas individuals in other rings will be offered vaccine only after some delay. The differential incidence of disease between rings with immediate versus delayed vaccination will be a measure of vaccine effectiveness. Enrolling new rings as Ebola cases are detected is a form of stepped rollout that, by focusing the trial in areas of known

Strategies for vaccine trials in challenging


conditions. (A) A classic iRCT. Randomization has occurred within the whole population, and the trial can only start when all of the centers are ready. The red line represents the maximum number of participants the trial could enroll, given increasing logistical capacity. The area of the box is the total person-time in the trial; it is the size of the trial measured in person-weeks of observation. **(B)** Illustration of stepped rollout (beginning the trial at each center when that center becomes ready to participate) and adaptive design [planning to add persons in new centers (green) and/or extend person-time of observation in existing centers (yellow), depending on incidence]. The estimated person-time required to do the trial (purple box) is the same as in (A), but because under stepped rollout the trial can start earlier, it can end earlier. Parameters are all illustrative, and (for simplicity) centers are shown as becoming ready in a linear manner with time.

transmission, is particularly well suited to circumstances of spotty and declining incidence. The design is adaptive as well, adding rings until there is sufficient statistical evidence to stop the trial, because at that point there is either enough evidence to declare the vaccine efficacious (success) or no reasonable likelihood of garnering such evidence by continuing the trial (futility). In addition, to improve comparability of the risk between vaccinated and not-yet-vaccinated people, immediate-vaccination rings can be matched for analysis with delayed rings that are similar in certain ways (e.g., geographically proximate rings).

Limited infrastructure, unpredictable variation in incidence, and a public health imperative to provide vaccine as quickly as possible are common in vaccine efficacy trials, even outside public health emergencies. Conduct of vaccine trials in outbreak settings and in populations most likely to benefit from vaccination is fraught with difficulties

¹Center for Communicable Disease Dynamics and Departments of Epidemiology and Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA. ²Department of Global Health and Population, Harvard T. H. Chan School of Public Health and Center for Bioethics, Harvard Medical School, Boston, MA, USA. ³Center for Inference and Dynamics of Infectious Diseases, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ⁴Department of Biostatistics, University of Washington, Seattle, WA 98105, USA. ⁵Center for Communicable Disease Dynamics and Departments of Epidemiology and Biostatistics, Harvard T. H. Chan School of Public Health, and Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA. ⁶Center for Inference and Dynamics of Infectious Diseases, Department of Biostatistics, College of Public Health and Health Professions, and College of Medicine, University of Florida, Gainesville, FL, USA. ⁷Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA. ⁸Center for Comprehensive Access and Delivery Research and Evaluation, Iowa Veterans Affairs Health Care System, Iowa City, IA, USA. ⁹Epicentre, Paris, France. *Corresponding author. E-mail: mlipsitc@hsph.harvard.edu (M.L.); Rebecca.grais@epicentre.msf.org (R.F.G.)†Present address: Visiting Professor, Department of Infectious Disease Epidemiology, Imperial College London, London, UK.

Strategies for vaccine trials



but reveals essential information about vaccine performance. Trial designs that are appropriately adapted to the most challenging settings are sorely needed, not only to improve the external validity of trial results but also to ensure that vaccine quickly reaches those most in need.

Outside the Ebola context, feasibility of particular designs will depend not only on the epidemiology of the relevant disease (time and spatial scale of transmission, ease of diagnosis, etc.) but also on the characteristics of the vaccines being tried (including number of doses required, timing of immunogenicity, and potential for post-exposure effectiveness). Ethical considerations of speeding the availability of possibly efficacious vaccines to large numbers of people will need to be balanced against the need for evaluation of vaccine efficacy so that resources can be concentrated on effective interventions. But discussions of ethical, logistical, and statistical considerations in trial design take time, and rapid implementation of studies is important for timely and reliable results before the epidemic wanes. The more such discussions can take place outside emergencies and establish general principles to inform vaccine trial designs in future outbreaks, the more effective the responses to such outbreaks will be. ■

REFERENCES AND NOTES

1. WHO high-level meeting on Ebola vaccines access and financing, 23 October 2014; http://apps.who.int/iris/bitstream/10665/137184/1/WHO_EVD_Meet_EMP_14.2_eng.pdf?ua=1
2. J. H. Giahvye, Liberia begins clinical trial for Ebola vaccines as outbreak ebbs. Reuters, 2 February 2015; www.reuters.com/article/2015/02/02/

health-ebola-vaccines-idU5L6NOVC2AE20150202 (2015).

3. A. Maxmen, Why we're still waiting on an Ebola vaccine. Al Jazeera America, 11 March 2015; <http://america.aljazeera.com/articles/2015/3/11/why-were-still-waiting-on-an-ebola-vaccine.html>
4. SAGE Working Group on Vaccination in Acute Humanitarian Emergencies, Vaccination in acute humanitarian emergencies: A framework for decision-making (WHO, Geneva, 2013; www.who.int/iris/handle/10665/92462)
5. C. Adebamowo et al., *Lancet* **384**, 1423 (2014).
6. J. P. Matts, J. M. Lachin, *Control. Clin. Trials* **9**, 327 (1988).
7. G. King et al., *Lancet* **373**, 1447 (2009).
8. G. King et al., *J. Policy Anal. Manage.* **26**, 479 (2007).
9. C. C. Iwuiji et al., *Trials* **14**, 230 (2013).
10. C. Jennison, B. Turnbull, Group sequential methods with applications to clinical trials, 2000; Chapman-Hall/CRC, Boca Raton, FL.
11. WHO, WHO high-level meeting on Ebola vaccines access and financing: Summary report, 23 October 2014; http://apps.who.int/iris/bitstream/10665/137184/1/WHO_EVD_Meet_EMP_14.2_eng.pdf?ua=1
12. H. Branswell, Improved Ebola situation in Liberia may complicate vaccine trials. *Scientific American*; www.scientificamerican.com/article/improved-ebola-situation-liberia-may-complicate-vaccine-trials (2014).
13. F. Fleck, A. Leshner, *Bull. World Health Organ.* **93**, 7 (2015).
14. NIAID, PREVAIL Phase 2/3 clinical trial of investigational Ebola vaccines, 2 February 2015; www.niaid.nih.gov/news/QA/Pages/EbolaVaxResultsQA.aspx (2015).
15. World Health Organization, "Experimental Ebola Vaccines. Situation report, 1 October 2014; www.who.int/mediacentre/news/ebola/01-october-2014/en/" (2014).
16. WHO/MSF/NIPH, Ebola vaccine efficacy trial ready to launch in Guinea, 5 March 2015; www.who.int/mediacentre/news/releases/2015/ebola-vaccine-trial/en/

ACKNOWLEDGMENTS

We thank B. Bloom, C. Donnelly, J. Leaning, and D. Wikler for helpful discussions and C. Worthy for help with the figure. M.L. and M.E.H. were supported by award U54GM088558, and M.E.H. and I.M.L. by award U54GM11274 from the National Institute of General Medical Sciences (NIGMS). The content is solely the responsibility of the authors and does not necessarily represent the official views of NIGMS, NIH, or Médecins sans Frontières.

10.1126/science.aaa3178